APA (7th ed.) Citation

Sun, S., Fulati, W., Shen, L., Wu, M., Huang, Z., Qian, W., . . . Xie, Y. (2023). Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells. Cancer Medicine, 12(12), 12975. https://doi.org/10.1002/cam4.5969

Chicago Style (17th ed.) Citation

Sun, Shunrong, et al. "Maintenance Regimen of GM‐CSF with Rituximab and Lenalidomide Improves Survival in High‐risk B‐cell Lymphoma by Modulating Natural Killer Cells." Cancer Medicine 12, no. 12 (2023): 12975. https://doi.org/10.1002/cam4.5969.

MLA (9th ed.) Citation

Sun, Shunrong, et al. "Maintenance Regimen of GM‐CSF with Rituximab and Lenalidomide Improves Survival in High‐risk B‐cell Lymphoma by Modulating Natural Killer Cells." Cancer Medicine, vol. 12, no. 12, 2023, p. 12975, https://doi.org/10.1002/cam4.5969.